Impact and Effectiveness of Monovalent Rotavirus Vaccine in Armenian Children

Abstract

RV1 is effective in young Armenian children and substantially reduced rotavirus hospitalizations shortly after introduction.

Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008–16: findings from the Global Rotavirus Surveillance Network

“…8 Individual country reports also indicate reductions in hospital admissions for rotavirus gastroenteritis among children younger than 5 years, ran ging from 23% to 69% in diverse settings worldwide. 3,7,[9][10][11][12] WHO recommends the use of rotavirus vaccines in all national immunisation programmes globally, particu larly in countries with high diarrhoeal mortality among children. 13 Two rotavirus vaccines are currently in routine use globally: the monovalent Rotarix (RV1; GlaxoSmithKline, Rixensart, Belgium) and pentavalent RotaTeq (RV5; Merck, West Point, PA, USA).…”

Epidemiology and economic losses of rotavirus infection associated with hospitalization of Armenian children

“…The prevalence of RV infection in the Republic of Armenia generally coincides with the international statistical indices [10]. RV is documented to cause 38% of acute gastroenteritis hospitalizations among children aged < 5 years [11]. The Republic of Armenia was one of the two earliest countries in the Newly Independent States to introduce rotavirus vaccine into its national immunization program.…”

“…The Republic of Armenia was one of the two earliest countries in the Newly Independent States to introduce rotavirus vaccine into its national immunization program. In November 2012, RV1 (Rotarix) was introduced for Armenian infants of ages 6 and 12 weeks [11,12]. Despite this fact, the hospitalization associated with RV gastroenteritis remains significant.…”

Rotavirus Vaccines: Current Global Impact and Future Perspectives

“…For example, three years after vaccine introduction, rotavirus hospitalizations in children <5 years of age declined by 69% in Armenia and 64% in Ghana, compared with their respective prevaccine rates [23,24]. Five years after introduction in South Africa, diarrhea hospitalizations in children <5 years of age decreased by 53%, with the most significant reductions in children <12 months and, to a lesser extent, children 12–23 months of age [25].…”

“…Vaccine effectiveness (VE) in high-income countries has been estimated as 79–100% [19]. New data continues to document lower VE in low- and middle-income countries; recent point estimates for RV1 VE against hospitalization and other healthcare encounters have been as high as 79 and 62% in Moldova and Armenia, respectively, and between 50 and 60% in Bolivia, Botswana, Malawi and Zambia [24,33–37]. For RV5, VE was recently estimated to be 80% in Rwanda and 45% in Nicaragua [38,39].…”